Vertex stock: Officer files notice for proposed share sale
Published on 11/14/2026 at 11:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSInsider Filing Shapes Weekly Focus
- A Form 144 notice dated November 12 covered a proposed share sale by Vertex officer Charles F. Wagner Jr.
- The notice listed Nasdaq as the exchange and identified November 12 as the planned sale date.
On November 12, Vertex Pharmaceuticals officer Charles F. Wagner Jr. filed notice of a proposed sale of company shares. The filing was reported in the StockTitan summary of the Form 144 submitted to the U.S. Securities and Exchange Commission.
Planned Transaction, Not Completed Sale
The notice covered 15,286 common shares with an aggregate market value of 8,374,740.82 US dollars. It listed November 12 as the approximate sale date and Nasdaq as the exchange. The filing also recorded August 10 as the date of the Rule 10b5-1 plan or trading instruction, if applicable.
The notice concerns a proposed transaction rather than a completed disposal. It therefore adds an insider-trading item to the week's investor agenda without changing Vertex's operating outlook.
Vertex Stock Quote
Vertex stock traded at 488.68 euros on Lang & Schwarz at 11:27 CET on Saturday, November 14.
Vertex Pharmaceuticals at a Glance
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Home exchange: Nasdaq
- Lang & Schwarz quote: 488.68 euros on Saturday, November 14, 2026, at 11:27 CET
- Proposed shares: 15,286 common shares
- Approximate sale date: November 12, 2026
The broader U.S. equity market can be followed in Current market reports.
